IRIS PubliCatt
PubliCatt è il repository istituzionale ad accesso aperto dell'Università Cattolica del Sacro Cuore, dove gli utenti autorizzati afferenti all'Ateneo provvedono direttamente e autonomamente a depositare e a rendere visibili le proprie pubblicazioni, inserendo i dati descrittivi del documento stesso ("metadati", quali il titolo, autore, abstract, etc.) e, laddove possibile, il testo della pubblicazione stessa (full-text).
PubliCatt utilizza la piattaforma IRIS (Institutional Research Information System) sviluppata da CINECA.
EnglishBackground and Objective: Administration of carbapenems to β-lactam-allergic patients has always been considered potentially harmful because of a 47.4% rate of cross-reactivity to imipenem reported in a single study. Nevertheless, recent studies have shown that the rate of cross-reactivity of imipenem and meropenem with penicillins is lower than 1%. The aim of this study was to evaluate the possibility of using ertapenem in patients with an established IgE-mediated β-lactam allergy. Patients and Methods: We studied all participants who came to our allergy unit and had a clinical history of immediate hypersensitivity reactions to β-lactams. The inclusion criteria were a positive skin test result to at least 1 β-lactam molecule and/or positive specific IgE (when available). All participants underwent immediate-type skin tests with several β-lactam molecules including ertapenem. Challenges with intravenous ertapenem were performed on 2 different days in patients with negative skin test results. Results: We examined 49 patients with a clinical history of immediate reactions to β-lactams. All the patients had positive skin tests and/or positive specific IgE to at least 1 β-lactam reagent and negative carbapenem skin tests. Thirty-six patients agreed to undergo the challenges and 35 tolerated the full dose of ertapenem. Conclusions: The practice of avoiding carbapenems in patients with β-lactam allergy should be abandoned considering the very low rate of cross-reactivity. β-Lactam-allergic patients who need ertapenem therapy should undergo skin tests and, if negative, a graded challenge to assess tolerability. Key words: β-lactams. IgE-mediated hypersensitivity. Ertapenem. Cross-reactivity.
Buonomo, A., Pascolini, L., Rizzi, A., Aruanno, A., Pecora, V., Ricci, A. G., Mezzacappa, S., Di Rienzo, A., Centrone, M., Nucera, E., Schiavino, D., Cross-reactivity and tolerability of Ertapenem in patients with IgE-mediated hypersensitivity to β-lactams, <<JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY>>, 2016; (2): 100-105. [doi:10.18176/jiaci.0019] [http://hdl.handle.net/10807/77019]
| Autori: | ||
| Titolo: | Cross-reactivity and tolerability of Ertapenem in patients with IgE-mediated hypersensitivity to β-lactams | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.18176/jiaci.0019 | |
| Data di pubblicazione: | 2016 | |
| Abstract: | Background and Objective: Administration of carbapenems to β-lactam-allergic patients has always been considered potentially harmful because of a 47.4% rate of cross-reactivity to imipenem reported in a single study. Nevertheless, recent studies have shown that the rate of cross-reactivity of imipenem and meropenem with penicillins is lower than 1%. The aim of this study was to evaluate the possibility of using ertapenem in patients with an established IgE-mediated β-lactam allergy. Patients and Methods: We studied all participants who came to our allergy unit and had a clinical history of immediate hypersensitivity reactions to β-lactams. The inclusion criteria were a positive skin test result to at least 1 β-lactam molecule and/or positive specific IgE (when available). All participants underwent immediate-type skin tests with several β-lactam molecules including ertapenem. Challenges with intravenous ertapenem were performed on 2 different days in patients with negative skin test results. Results: We examined 49 patients with a clinical history of immediate reactions to β-lactams. All the patients had positive skin tests and/or positive specific IgE to at least 1 β-lactam reagent and negative carbapenem skin tests. Thirty-six patients agreed to undergo the challenges and 35 tolerated the full dose of ertapenem. Conclusions: The practice of avoiding carbapenems in patients with β-lactam allergy should be abandoned considering the very low rate of cross-reactivity. β-Lactam-allergic patients who need ertapenem therapy should undergo skin tests and, if negative, a graded challenge to assess tolerability. Key words: β-lactams. IgE-mediated hypersensitivity. Ertapenem. Cross-reactivity. | |
| Lingua: | Inglese | |
| Rivista: | ||
| Citazione: | Buonomo, A., Pascolini, L., Rizzi, A., Aruanno, A., Pecora, V., Ricci, A. G., Mezzacappa, S., Di Rienzo, A., Centrone, M., Nucera, E., Schiavino, D., Cross-reactivity and tolerability of Ertapenem in patients with IgE-mediated hypersensitivity to β-lactams, <<JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY>>, 2016; (2): 100-105. [doi:10.18176/jiaci.0019] [http://hdl.handle.net/10807/77019] | |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |
File in questo prodotto:
http://hdl.handle.net/10807/77019
Copyright © 2021